SlideShare a Scribd company logo
1 of 1
Epigenetic Study Aims to Reveal Etiology of Schizophrenia
Marissa Cohen1
& Katherine Kenneweg2
1
Dept. of Zoology, Miami University, Oxford, Ohio; 2
Dept. of Microbiology, Miami University, Oxford, Ohio
What is Epigenetics?
GABA
Gamma-aminobutyric acid (GABA) is an important inhibitory neurotransmitter in the mammalian
central nervous system. Glutamic acid decarboxylase (GAD) is responsible for the conversion of
glutamate to GABA, and is the limiting factor in regulating levels of CNS GABA. In several brain
sites, GAD67 is colocalized to the same GABAergic interneurons as Reelin (RELN), an extracellular
matrix protein that subserves synaptic plasticity in adult brain and that helps in normal lamination of
the embryonic brain. Recent studies have shown that the genes that encode reelin and GAD67 are
downregulated at both transcriptional and translational levels in the schizophrenic brain. These
downregulations are believed to be caused by increases in methylation at the promoter of each gene
regulated by DNA Methyltransferase 1 (DNMT), which is upregulated in GABAergic interneurons.
Furthermore, the promoters of RELN and GAD67 are embedded within CpG islands, areas of DNA
known to be epigenetically regulated by hypermethylation. (Costa, Grayson, & Guidotti, 2003)
Understanding epigenetic mechanisms regulating RELN and GAD67 transcription is likely to lead
to the discovery of new drugs able to reprogram transcriptional programs that support
neuropathology. Thus, inhibiting DNMT activity in schizophrenics along the RELN or GAD67
promoters should decrease schizophrenic symptoms, but the lack of specific DNMT inhibitors
prevents further investigation of this hypothesis. However, because histone deacetylase (HDAC)
interacts with DNMT to inactivate chromatin, HDAC inhibitors can be used to prevent DNMT activity.
The HDAC inhibitor, valproate, has shown to lead to an increase in histone acetylation, thereby
counteracting the effects of DNMT. (Roth, Lubin, Sodhi, & J.E., 2009)
Histone Modification
Several recent research studies have found significant
differences in postmortem brains in histone modifications when
compared to brains from individuals who did not suffer from
schizophrenia. In particular, elevated levels of enzyme histone
deacetylase 1, HDAC1, has been found in diseased samples as
well as decreased levels of GAD67. Further, at the GAD67
promoter, lower H3K4 methylation has been observed, thus
lowering GAD67 expression. In general, HDAC has been shown
to improve neurodegenerative and cognitive phenotypes, boost
memory and learning tasks, and lower ischemic damage in wild
type mice. More specifically, HDAC1 negatively mediated by
siRNA or by pharmacological means has resulted in increased
cell death and impaired learning in studies. Normally, HDAC1
corrects DNA damage and prevents ischemic cell death, thus
indicating that the pathogenic processes included in
schizophrenia increase HDAC1 expression and the disorder is
propagated by the increase. Common antidepressants used to
treat schizophrenia able to alter the chromatin, are known to
alleviate some of the symptoms of the disorder. These MAOIs
have H3K4 histone demethylase inhibitory activity, thus
indicating that H3K4 methylation may be integral to
schizophrenia development. Other histone modifications
including in methylated lysines in H3K27 and dimethylated
H3K9, methylated arginine in H3R17, and phosphorylated
serine and acetylated acetylation in H3S10K14, show significant
differences from normal brains are currently undergoing further
study. Researchers are now utilizing peripheral blood
mononuclear cells to investigate global DNA methylation levels
(Gavin & Shrama, 2009).
Effects of Environment
Epigenetic modifications are caused by environmental conditions, both neonatal and postnatal.
Significant research has been done to investigate these effects and possible contributions to
diseases such as schizophrenia in the hope that finding these correlations will lead to better disease
prevention in the future. One study investigating the effect of maternal nutrition found that famine
conditions for the mother could increase risk of schizophrenia for the fetus in utero two-fold. Thus,
malnutrition may trigger gene misregulation and differential methylation. Another possible cause of
epigenetic changes may be parental rearing. Rat studies found that maternal grooming of pups
caused methylation and histone modifications in the glucocorticoid receptor gene promoter in the
hippocampus, which is involved in memory, emotion, navigation, and spatial orientation, all of which
are areas of interest to schizophrenia researchers.
Researchers have also studied the effect of drug use and environmental pressures such as
stress. DNMT1 expression has been found to change and cause schizophrenia-like symptoms in
chronic methanphetamine users. Cocaine use has been linked to unusual histone acetylation
resulting from decreased HDAC activity, as have cannabis and the mood stabilizer and
anticonvulsant valproate. Finally, fear and stress revealed demethylation and increased expression
of RELN., The increased stress of urbanicity has shown higher incidence of schizophrenia when
compared to rural areas. (Oh, 2008).
What is Schizophrenia?
Schizophrenia is a chronic psychotic disorder characterized by
disturbed perceptions, emotions, behavior and thinking. There are
approximately 2 million affected individuals in the United States,
about 1% of the population, with a worldwide estimate is 24 million.
Occurrance is fourfold higher in men. There are three main
categories of schizophrenia – disorganized type, catatonic type,
and paranoid type. These categories all have some overlapping
clinical features including delusions, thought disorder,
hallucinations, inappropriate or flat emotions, difficulty screening
environmental stimuli, impaired social interaction skills, and
personal identity uncertainty. The DSM-IV-TR has 4 diagnostic
contentions. The first set is symptomatically based. Next, the
individual’s occupation, relationships, or self-care is markedly
different from prior to disorder onset. The affected period must
extend at least six months, and a change in behaviors and thoughts
leading to diagnosis cannot be the result of another medical
condition or substance (Nevid, 2008).
Studies done with monozygotic twins yielded concordance
rates of 48% and 3.6% in dizygotic twins (Gottesman, 1991). These
values support the conclusion that there is a significant genetic
cause of schizophrenia, but that environmental factors contribute to
the disorder, as well. This is further supported by research which
reported that children of two schizophrenic parents had only a 45%
chance of developing schizophrenia themselves.
Though one cause of schizophrenia has not been identified,
researchers have suggested viral, genetic, nutritional,
neurotransmitter changes, and brain mass decrease (Brown, Begg,
Gravenstein, Schaefer, Wyatt, Bresnahan, et al., 2004). There is no
treatment for schizophrenia, although antipsychotic medications
can reduce symptoms. Researchers hope to find the etiology of the
disorder in order to find a cure for schizophrenia.
References
Brown, AS, Begg, MD, Gravenstein, S, Schaefer, CA, Wyatt, RJ. Bresnahan, M, et al. (2004). Serological evidence of prenatal influenza in the etiology of
schizophrenia. Archives of Gen. Psychiatry. 61, 774-780
Costa, E, Grayson, D, & Guidotti, A. (2003). Epigenetic functions in schizophrenia. Molecular interventions, 220-229.
Gavin, DP & Sharma, RP. (2009). Histone modifications, DNA methylation, and Schizophrenia. Neuroscience and Biobehavioral Reviews 34, 882-888
Fatemi, H, Stary, J, Earle, J, Araghi-Niknam, M, & Eagan, E. (2005). GABAergic dysfunction in schizophrenia and mood disorders as feflected by decreased
levels of gluamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophrenia Research , 109-122.
Gottesman, II. (1991). Schizophrenia genetics: The origins of madness. New York: Freeman.
Narr, KL, Thompson, PM, Sharma, T, Moussai, J, Cannestra, AF, Toga, AW. (2000). Mapping Corpus Callosum Morphology in Schizophrenia. Cerebral
Cortex. 10(1), 40-49.
Nevid, JS, Rathus, SA, and Greene, B. (2008). Abnormal Psychology in a Changing World: Seventh edition.
Oh, G and Petronis, A. (2008). Environmental Studies of Schizophrenia Through the Prism of Epigenetics. Schizophr. Bull. 34(6), 1122-1129.
Roth, T, Lubin, F, Sodhi, M, and JE, K. (2009). Epigenetic mechanisms in schizophrenia. Biochimica et Biophysica Acta , 869-877.
Thompson, PM, Vidal, C, Giedd, JN, Gochman, P, Blumenthal, J, Nicolson, R, Toga, AW, and Rapoport, JL. (2001). Mapping adolescent brain change
reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. PNAS. 11650-11655.
“The difference between genetics and epigenetics can probably be
compared to the difference between writing and reading a book.
Once a book is written, the text (the genes or DNA: stored
information) will be the same in all the copies distributed to the
interested audience. However, each individual reader of a given
book may interpret the story slightly differently, with varying emotions
and projections as they continue to unfold the chapters. In a very
similar manner, epigenetics would allow different interpretations of a
fixed template (the book or genetic code) and result in different read-
outs, dependent upon the variable conditions under which this
template is interrogated.”
- Thomas Jenuwein (Vienna, Austria)
(Thompson, et. al., 2001) (Narr, et al., 2000)
Background image courtesy of The Royal Society of New Zealand
(http://nihroadmap.nih.gov/EPIGENOMICS/images/epigeneticmechanisms)
Conclusions
Recent research provides evidence that although schizophrenia
is affected by genetics, epigenetics play a major role in the
development of the disorder, as well. Environmental conditions an
individual encounters during his life both in his mother’s womb and
after birth lead to methylation, acetylation, and phosphorylation of
DNA and histone tails. These modifications, though normal, may
lead to severe consequences if done in specific areas of the brain
and within certain genes. Methylation of the promoters of certain
genes, such as GAD67, are obvious causes of schizophrenia.
Emerging neurobiological evidence indicates that many of the genes
potentially involved in etiology of schizophrenia may also be involved
in pathology of bipolar disorder and to a lesser degree in major
depression and other neurodevelopmental disorders like autism
(Fatemi, Stary, Earle, Araghi-Niknam, & Eagan, 2005). By studying
the major epigenetic mechanisms implicated in schizophrenia and
these other disorders, it seems we are paving a road toward
treatment and prevention.

More Related Content

What's hot

The ADHD Epidemic in America
The ADHD Epidemic in AmericaThe ADHD Epidemic in America
The ADHD Epidemic in Americaworldwideww
 
Cannabinoids and neuroprotection
Cannabinoids and neuroprotectionCannabinoids and neuroprotection
Cannabinoids and neuroprotectionIan Mitchell
 
Luisetto m, ahmed y r, behzad ni, farhan a k, ghulam r m. immune shock chron...
Luisetto m, ahmed y r, behzad ni, farhan a k, ghulam r m. immune shock  chron...Luisetto m, ahmed y r, behzad ni, farhan a k, ghulam r m. immune shock  chron...
Luisetto m, ahmed y r, behzad ni, farhan a k, ghulam r m. immune shock chron...M. Luisetto Pharm.D.Spec. Pharmacology
 
Chronic Neuroinflammation in Alzheimer’s Disease New Perspectives Animal Mode...
Chronic Neuroinflammation in Alzheimer’s Disease New Perspectives Animal Mode...Chronic Neuroinflammation in Alzheimer’s Disease New Perspectives Animal Mode...
Chronic Neuroinflammation in Alzheimer’s Disease New Perspectives Animal Mode...Niloo Karunaweera
 
Anti-NMDA Receptor Encephalitis
Anti-NMDA Receptor Encephalitis Anti-NMDA Receptor Encephalitis
Anti-NMDA Receptor Encephalitis Ade Wijaya
 
Is there an epidemic of mental illness? If so, what causes it?
Is there an epidemic of mental illness? If so, what causes it?Is there an epidemic of mental illness? If so, what causes it?
Is there an epidemic of mental illness? If so, what causes it?Richard Gill
 
Treating_progressive_MS_KS_20180414
Treating_progressive_MS_KS_20180414Treating_progressive_MS_KS_20180414
Treating_progressive_MS_KS_20180414Klaus Schmierer
 
THE ENDOCANNABINOID SYSTEM - Cady Wellness Institute
THE ENDOCANNABINOID SYSTEM - Cady Wellness InstituteTHE ENDOCANNABINOID SYSTEM - Cady Wellness Institute
THE ENDOCANNABINOID SYSTEM - Cady Wellness InstituteLouis Cady, MD
 
The Millennium-Warrior Angels Foundation 3 year TBI study
The Millennium-Warrior Angels Foundation 3 year TBI study The Millennium-Warrior Angels Foundation 3 year TBI study
The Millennium-Warrior Angels Foundation 3 year TBI study Andrew Marr
 
Genomic and proyeomic markers in forensic psychiatry
Genomic and proyeomic markers in forensic psychiatryGenomic and proyeomic markers in forensic psychiatry
Genomic and proyeomic markers in forensic psychiatryAdonis Sfera, MD
 
IMPACT_Final_Presentation2
IMPACT_Final_Presentation2IMPACT_Final_Presentation2
IMPACT_Final_Presentation2Anant Naik
 
Luisetto m et al (2017) immune shock chronologic event in some brain patho...
Luisetto m et al  (2017) immune shock   chronologic event in some brain patho...Luisetto m et al  (2017) immune shock   chronologic event in some brain patho...
Luisetto m et al (2017) immune shock chronologic event in some brain patho...M. Luisetto Pharm.D.Spec. Pharmacology
 

What's hot (18)

The ADHD Epidemic in America
The ADHD Epidemic in AmericaThe ADHD Epidemic in America
The ADHD Epidemic in America
 
Cannabinoids and neuroprotection
Cannabinoids and neuroprotectionCannabinoids and neuroprotection
Cannabinoids and neuroprotection
 
Luisetto m, ahmed y r, behzad ni, farhan a k, ghulam r m. immune shock chron...
Luisetto m, ahmed y r, behzad ni, farhan a k, ghulam r m. immune shock  chron...Luisetto m, ahmed y r, behzad ni, farhan a k, ghulam r m. immune shock  chron...
Luisetto m, ahmed y r, behzad ni, farhan a k, ghulam r m. immune shock chron...
 
Chronic Neuroinflammation in Alzheimer’s Disease New Perspectives Animal Mode...
Chronic Neuroinflammation in Alzheimer’s Disease New Perspectives Animal Mode...Chronic Neuroinflammation in Alzheimer’s Disease New Perspectives Animal Mode...
Chronic Neuroinflammation in Alzheimer’s Disease New Perspectives Animal Mode...
 
Gescher et al-2018-frontiers_in_psychiatry
Gescher et al-2018-frontiers_in_psychiatryGescher et al-2018-frontiers_in_psychiatry
Gescher et al-2018-frontiers_in_psychiatry
 
Anti-NMDA Receptor Encephalitis
Anti-NMDA Receptor Encephalitis Anti-NMDA Receptor Encephalitis
Anti-NMDA Receptor Encephalitis
 
Is there an epidemic of mental illness? If so, what causes it?
Is there an epidemic of mental illness? If so, what causes it?Is there an epidemic of mental illness? If so, what causes it?
Is there an epidemic of mental illness? If so, what causes it?
 
Treating_progressive_MS_KS_20180414
Treating_progressive_MS_KS_20180414Treating_progressive_MS_KS_20180414
Treating_progressive_MS_KS_20180414
 
Tryptophan and madness
Tryptophan and madnessTryptophan and madness
Tryptophan and madness
 
Huntington’s disease
Huntington’s diseaseHuntington’s disease
Huntington’s disease
 
THE ENDOCANNABINOID SYSTEM - Cady Wellness Institute
THE ENDOCANNABINOID SYSTEM - Cady Wellness InstituteTHE ENDOCANNABINOID SYSTEM - Cady Wellness Institute
THE ENDOCANNABINOID SYSTEM - Cady Wellness Institute
 
Alcohol dependence, womanizing & treament,a study pdf.
Alcohol dependence, womanizing & treament,a study pdf.Alcohol dependence, womanizing & treament,a study pdf.
Alcohol dependence, womanizing & treament,a study pdf.
 
Alcohol dependence, womanizing & treament,a study pdf.
Alcohol dependence, womanizing & treament,a study pdf.Alcohol dependence, womanizing & treament,a study pdf.
Alcohol dependence, womanizing & treament,a study pdf.
 
Neuroscienza dei comportamenti suicidari
Neuroscienza dei comportamenti suicidariNeuroscienza dei comportamenti suicidari
Neuroscienza dei comportamenti suicidari
 
The Millennium-Warrior Angels Foundation 3 year TBI study
The Millennium-Warrior Angels Foundation 3 year TBI study The Millennium-Warrior Angels Foundation 3 year TBI study
The Millennium-Warrior Angels Foundation 3 year TBI study
 
Genomic and proyeomic markers in forensic psychiatry
Genomic and proyeomic markers in forensic psychiatryGenomic and proyeomic markers in forensic psychiatry
Genomic and proyeomic markers in forensic psychiatry
 
IMPACT_Final_Presentation2
IMPACT_Final_Presentation2IMPACT_Final_Presentation2
IMPACT_Final_Presentation2
 
Luisetto m et al (2017) immune shock chronologic event in some brain patho...
Luisetto m et al  (2017) immune shock   chronologic event in some brain patho...Luisetto m et al  (2017) immune shock   chronologic event in some brain patho...
Luisetto m et al (2017) immune shock chronologic event in some brain patho...
 

Viewers also liked

Case Study: Schizophrenia
Case Study: SchizophreniaCase Study: Schizophrenia
Case Study: SchizophreniaKelly Tran
 
235045552 case-study-on-schizophrenia
235045552 case-study-on-schizophrenia235045552 case-study-on-schizophrenia
235045552 case-study-on-schizophreniahomeworkping3
 
Schizophrenia case history- prof. fareed minhas
Schizophrenia case history- prof. fareed minhasSchizophrenia case history- prof. fareed minhas
Schizophrenia case history- prof. fareed minhasRawalpindi Medical College
 
Schizophrenia - Psychiatry Case Presentation
Schizophrenia - Psychiatry Case PresentationSchizophrenia - Psychiatry Case Presentation
Schizophrenia - Psychiatry Case Presentationcandicelainereyes
 
Powerpoint final case study presentation
Powerpoint final case study presentationPowerpoint final case study presentation
Powerpoint final case study presentationJLUM13
 
A Case Study on Schizophrenia
 A Case Study on Schizophrenia A Case Study on Schizophrenia
A Case Study on SchizophreniaReeba Sara Koshy
 

Viewers also liked (12)

Poster_Fifer
Poster_FiferPoster_Fifer
Poster_Fifer
 
Schizophrenia Final
Schizophrenia FinalSchizophrenia Final
Schizophrenia Final
 
Schizophrenia
SchizophreniaSchizophrenia
Schizophrenia
 
Case presentation
Case presentationCase presentation
Case presentation
 
Case Study: Schizophrenia
Case Study: SchizophreniaCase Study: Schizophrenia
Case Study: Schizophrenia
 
235045552 case-study-on-schizophrenia
235045552 case-study-on-schizophrenia235045552 case-study-on-schizophrenia
235045552 case-study-on-schizophrenia
 
Schizophrenia case history- prof. fareed minhas
Schizophrenia case history- prof. fareed minhasSchizophrenia case history- prof. fareed minhas
Schizophrenia case history- prof. fareed minhas
 
Schizophrenia
SchizophreniaSchizophrenia
Schizophrenia
 
Schizophrenia - Psychiatry Case Presentation
Schizophrenia - Psychiatry Case PresentationSchizophrenia - Psychiatry Case Presentation
Schizophrenia - Psychiatry Case Presentation
 
Powerpoint final case study presentation
Powerpoint final case study presentationPowerpoint final case study presentation
Powerpoint final case study presentation
 
Patient Case Presentation
Patient Case PresentationPatient Case Presentation
Patient Case Presentation
 
A Case Study on Schizophrenia
 A Case Study on Schizophrenia A Case Study on Schizophrenia
A Case Study on Schizophrenia
 

Similar to ZOO 400

Back to dsm : psychiatry rethinking mental illness thomas r. insel, md philip...
Back to dsm : psychiatry rethinking mental illness thomas r. insel, md philip...Back to dsm : psychiatry rethinking mental illness thomas r. insel, md philip...
Back to dsm : psychiatry rethinking mental illness thomas r. insel, md philip...BARRY STANLEY 2 fasd
 
BIOMARKERS AND SCHIZOPHRENIA1233445677.ppt
BIOMARKERS AND SCHIZOPHRENIA1233445677.pptBIOMARKERS AND SCHIZOPHRENIA1233445677.ppt
BIOMARKERS AND SCHIZOPHRENIA1233445677.pptRobinBaghla
 
Molecular Substrates of Drug Abuse in a Schizophrenic Population
Molecular Substrates of Drug Abuse in a Schizophrenic PopulationMolecular Substrates of Drug Abuse in a Schizophrenic Population
Molecular Substrates of Drug Abuse in a Schizophrenic PopulationAlan Lesselyong
 
The neurobiology and pharmacotherapy of bipolar
The neurobiology and pharmacotherapy of bipolarThe neurobiology and pharmacotherapy of bipolar
The neurobiology and pharmacotherapy of bipolarNick Stafford
 
A guideline for discontinuing antiepileptic drugs in seizure-free patients – ...
A guideline for discontinuing antiepileptic drugs in seizure-free patients – ...A guideline for discontinuing antiepileptic drugs in seizure-free patients – ...
A guideline for discontinuing antiepileptic drugs in seizure-free patients – ...Dr. Rafael Higashi
 
jama letter- Rethinking Mental Illness
jama letter- Rethinking Mental Illnessjama letter- Rethinking Mental Illness
jama letter- Rethinking Mental IllnessBARRY STANLEY 2 fasd
 
Hanipsych, updates on neurobiology and neurotoxicity of depression
Hanipsych, updates on neurobiology and neurotoxicity of depressionHanipsych, updates on neurobiology and neurotoxicity of depression
Hanipsych, updates on neurobiology and neurotoxicity of depressionHani Hamed
 
Schizophrenia~Ketamine~Pterostilbene
Schizophrenia~Ketamine~PterostilbeneSchizophrenia~Ketamine~Pterostilbene
Schizophrenia~Ketamine~PterostilbeneDevender Palsa
 
djani_gvsp_poster
djani_gvsp_posterdjani_gvsp_poster
djani_gvsp_posterDylan Djani
 
Association study of the GSK-3B gene with tardive dyskinesia in European Cauc...
Association study of the GSK-3B gene with tardive dyskinesia in European Cauc...Association study of the GSK-3B gene with tardive dyskinesia in European Cauc...
Association study of the GSK-3B gene with tardive dyskinesia in European Cauc...Valerie Felton
 
Glutamate Hypothesis of Schizophrenia
Glutamate Hypothesis of SchizophreniaGlutamate Hypothesis of Schizophrenia
Glutamate Hypothesis of Schizophreniakhalid mansour
 
Epigenetic memory the lamarckian brain embj.201387637.full
Epigenetic memory the lamarckian brain embj.201387637.fullEpigenetic memory the lamarckian brain embj.201387637.full
Epigenetic memory the lamarckian brain embj.201387637.fullElsa von Licy
 
Hans Jürgen-Current situation and future perspetives of antipsychotics in sch...
Hans Jürgen-Current situation and future perspetives of antipsychotics in sch...Hans Jürgen-Current situation and future perspetives of antipsychotics in sch...
Hans Jürgen-Current situation and future perspetives of antipsychotics in sch...Fundación Ramón Areces
 

Similar to ZOO 400 (20)

laboratorio enzimas mitocondriales
laboratorio enzimas mitocondrialeslaboratorio enzimas mitocondriales
laboratorio enzimas mitocondriales
 
Back to dsm : psychiatry rethinking mental illness thomas r. insel, md philip...
Back to dsm : psychiatry rethinking mental illness thomas r. insel, md philip...Back to dsm : psychiatry rethinking mental illness thomas r. insel, md philip...
Back to dsm : psychiatry rethinking mental illness thomas r. insel, md philip...
 
BIOMARKERS AND SCHIZOPHRENIA1233445677.ppt
BIOMARKERS AND SCHIZOPHRENIA1233445677.pptBIOMARKERS AND SCHIZOPHRENIA1233445677.ppt
BIOMARKERS AND SCHIZOPHRENIA1233445677.ppt
 
Molecular Substrates of Drug Abuse in a Schizophrenic Population
Molecular Substrates of Drug Abuse in a Schizophrenic PopulationMolecular Substrates of Drug Abuse in a Schizophrenic Population
Molecular Substrates of Drug Abuse in a Schizophrenic Population
 
The neurobiology and pharmacotherapy of bipolar
The neurobiology and pharmacotherapy of bipolarThe neurobiology and pharmacotherapy of bipolar
The neurobiology and pharmacotherapy of bipolar
 
A guideline for discontinuing antiepileptic drugs in seizure-free patients – ...
A guideline for discontinuing antiepileptic drugs in seizure-free patients – ...A guideline for discontinuing antiepileptic drugs in seizure-free patients – ...
A guideline for discontinuing antiepileptic drugs in seizure-free patients – ...
 
jama letter- Rethinking Mental Illness
jama letter- Rethinking Mental Illnessjama letter- Rethinking Mental Illness
jama letter- Rethinking Mental Illness
 
Hanipsych, updates on neurobiology and neurotoxicity of depression
Hanipsych, updates on neurobiology and neurotoxicity of depressionHanipsych, updates on neurobiology and neurotoxicity of depression
Hanipsych, updates on neurobiology and neurotoxicity of depression
 
Schizophrenia~Ketamine~Pterostilbene
Schizophrenia~Ketamine~PterostilbeneSchizophrenia~Ketamine~Pterostilbene
Schizophrenia~Ketamine~Pterostilbene
 
djani_gvsp_poster
djani_gvsp_posterdjani_gvsp_poster
djani_gvsp_poster
 
Association study of the GSK-3B gene with tardive dyskinesia in European Cauc...
Association study of the GSK-3B gene with tardive dyskinesia in European Cauc...Association study of the GSK-3B gene with tardive dyskinesia in European Cauc...
Association study of the GSK-3B gene with tardive dyskinesia in European Cauc...
 
Glutamate Hypothesis of Schizophrenia
Glutamate Hypothesis of SchizophreniaGlutamate Hypothesis of Schizophrenia
Glutamate Hypothesis of Schizophrenia
 
FASD, Suicide and Epigenetics
FASD, Suicide and EpigeneticsFASD, Suicide and Epigenetics
FASD, Suicide and Epigenetics
 
M.Sc Presentation
M.Sc PresentationM.Sc Presentation
M.Sc Presentation
 
NEURO PAPER
NEURO PAPERNEURO PAPER
NEURO PAPER
 
Epigenetic memory the lamarckian brain embj.201387637.full
Epigenetic memory the lamarckian brain embj.201387637.fullEpigenetic memory the lamarckian brain embj.201387637.full
Epigenetic memory the lamarckian brain embj.201387637.full
 
Hans Jürgen-Current situation and future perspetives of antipsychotics in sch...
Hans Jürgen-Current situation and future perspetives of antipsychotics in sch...Hans Jürgen-Current situation and future perspetives of antipsychotics in sch...
Hans Jürgen-Current situation and future perspetives of antipsychotics in sch...
 
Schizophrenia
SchizophreniaSchizophrenia
Schizophrenia
 
Comment on microglia
Comment on microgliaComment on microglia
Comment on microglia
 
Glutamate 33
Glutamate 33Glutamate 33
Glutamate 33
 

ZOO 400

  • 1. Epigenetic Study Aims to Reveal Etiology of Schizophrenia Marissa Cohen1 & Katherine Kenneweg2 1 Dept. of Zoology, Miami University, Oxford, Ohio; 2 Dept. of Microbiology, Miami University, Oxford, Ohio What is Epigenetics? GABA Gamma-aminobutyric acid (GABA) is an important inhibitory neurotransmitter in the mammalian central nervous system. Glutamic acid decarboxylase (GAD) is responsible for the conversion of glutamate to GABA, and is the limiting factor in regulating levels of CNS GABA. In several brain sites, GAD67 is colocalized to the same GABAergic interneurons as Reelin (RELN), an extracellular matrix protein that subserves synaptic plasticity in adult brain and that helps in normal lamination of the embryonic brain. Recent studies have shown that the genes that encode reelin and GAD67 are downregulated at both transcriptional and translational levels in the schizophrenic brain. These downregulations are believed to be caused by increases in methylation at the promoter of each gene regulated by DNA Methyltransferase 1 (DNMT), which is upregulated in GABAergic interneurons. Furthermore, the promoters of RELN and GAD67 are embedded within CpG islands, areas of DNA known to be epigenetically regulated by hypermethylation. (Costa, Grayson, & Guidotti, 2003) Understanding epigenetic mechanisms regulating RELN and GAD67 transcription is likely to lead to the discovery of new drugs able to reprogram transcriptional programs that support neuropathology. Thus, inhibiting DNMT activity in schizophrenics along the RELN or GAD67 promoters should decrease schizophrenic symptoms, but the lack of specific DNMT inhibitors prevents further investigation of this hypothesis. However, because histone deacetylase (HDAC) interacts with DNMT to inactivate chromatin, HDAC inhibitors can be used to prevent DNMT activity. The HDAC inhibitor, valproate, has shown to lead to an increase in histone acetylation, thereby counteracting the effects of DNMT. (Roth, Lubin, Sodhi, & J.E., 2009) Histone Modification Several recent research studies have found significant differences in postmortem brains in histone modifications when compared to brains from individuals who did not suffer from schizophrenia. In particular, elevated levels of enzyme histone deacetylase 1, HDAC1, has been found in diseased samples as well as decreased levels of GAD67. Further, at the GAD67 promoter, lower H3K4 methylation has been observed, thus lowering GAD67 expression. In general, HDAC has been shown to improve neurodegenerative and cognitive phenotypes, boost memory and learning tasks, and lower ischemic damage in wild type mice. More specifically, HDAC1 negatively mediated by siRNA or by pharmacological means has resulted in increased cell death and impaired learning in studies. Normally, HDAC1 corrects DNA damage and prevents ischemic cell death, thus indicating that the pathogenic processes included in schizophrenia increase HDAC1 expression and the disorder is propagated by the increase. Common antidepressants used to treat schizophrenia able to alter the chromatin, are known to alleviate some of the symptoms of the disorder. These MAOIs have H3K4 histone demethylase inhibitory activity, thus indicating that H3K4 methylation may be integral to schizophrenia development. Other histone modifications including in methylated lysines in H3K27 and dimethylated H3K9, methylated arginine in H3R17, and phosphorylated serine and acetylated acetylation in H3S10K14, show significant differences from normal brains are currently undergoing further study. Researchers are now utilizing peripheral blood mononuclear cells to investigate global DNA methylation levels (Gavin & Shrama, 2009). Effects of Environment Epigenetic modifications are caused by environmental conditions, both neonatal and postnatal. Significant research has been done to investigate these effects and possible contributions to diseases such as schizophrenia in the hope that finding these correlations will lead to better disease prevention in the future. One study investigating the effect of maternal nutrition found that famine conditions for the mother could increase risk of schizophrenia for the fetus in utero two-fold. Thus, malnutrition may trigger gene misregulation and differential methylation. Another possible cause of epigenetic changes may be parental rearing. Rat studies found that maternal grooming of pups caused methylation and histone modifications in the glucocorticoid receptor gene promoter in the hippocampus, which is involved in memory, emotion, navigation, and spatial orientation, all of which are areas of interest to schizophrenia researchers. Researchers have also studied the effect of drug use and environmental pressures such as stress. DNMT1 expression has been found to change and cause schizophrenia-like symptoms in chronic methanphetamine users. Cocaine use has been linked to unusual histone acetylation resulting from decreased HDAC activity, as have cannabis and the mood stabilizer and anticonvulsant valproate. Finally, fear and stress revealed demethylation and increased expression of RELN., The increased stress of urbanicity has shown higher incidence of schizophrenia when compared to rural areas. (Oh, 2008). What is Schizophrenia? Schizophrenia is a chronic psychotic disorder characterized by disturbed perceptions, emotions, behavior and thinking. There are approximately 2 million affected individuals in the United States, about 1% of the population, with a worldwide estimate is 24 million. Occurrance is fourfold higher in men. There are three main categories of schizophrenia – disorganized type, catatonic type, and paranoid type. These categories all have some overlapping clinical features including delusions, thought disorder, hallucinations, inappropriate or flat emotions, difficulty screening environmental stimuli, impaired social interaction skills, and personal identity uncertainty. The DSM-IV-TR has 4 diagnostic contentions. The first set is symptomatically based. Next, the individual’s occupation, relationships, or self-care is markedly different from prior to disorder onset. The affected period must extend at least six months, and a change in behaviors and thoughts leading to diagnosis cannot be the result of another medical condition or substance (Nevid, 2008). Studies done with monozygotic twins yielded concordance rates of 48% and 3.6% in dizygotic twins (Gottesman, 1991). These values support the conclusion that there is a significant genetic cause of schizophrenia, but that environmental factors contribute to the disorder, as well. This is further supported by research which reported that children of two schizophrenic parents had only a 45% chance of developing schizophrenia themselves. Though one cause of schizophrenia has not been identified, researchers have suggested viral, genetic, nutritional, neurotransmitter changes, and brain mass decrease (Brown, Begg, Gravenstein, Schaefer, Wyatt, Bresnahan, et al., 2004). There is no treatment for schizophrenia, although antipsychotic medications can reduce symptoms. Researchers hope to find the etiology of the disorder in order to find a cure for schizophrenia. References Brown, AS, Begg, MD, Gravenstein, S, Schaefer, CA, Wyatt, RJ. Bresnahan, M, et al. (2004). Serological evidence of prenatal influenza in the etiology of schizophrenia. Archives of Gen. Psychiatry. 61, 774-780 Costa, E, Grayson, D, & Guidotti, A. (2003). Epigenetic functions in schizophrenia. Molecular interventions, 220-229. Gavin, DP & Sharma, RP. (2009). Histone modifications, DNA methylation, and Schizophrenia. Neuroscience and Biobehavioral Reviews 34, 882-888 Fatemi, H, Stary, J, Earle, J, Araghi-Niknam, M, & Eagan, E. (2005). GABAergic dysfunction in schizophrenia and mood disorders as feflected by decreased levels of gluamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophrenia Research , 109-122. Gottesman, II. (1991). Schizophrenia genetics: The origins of madness. New York: Freeman. Narr, KL, Thompson, PM, Sharma, T, Moussai, J, Cannestra, AF, Toga, AW. (2000). Mapping Corpus Callosum Morphology in Schizophrenia. Cerebral Cortex. 10(1), 40-49. Nevid, JS, Rathus, SA, and Greene, B. (2008). Abnormal Psychology in a Changing World: Seventh edition. Oh, G and Petronis, A. (2008). Environmental Studies of Schizophrenia Through the Prism of Epigenetics. Schizophr. Bull. 34(6), 1122-1129. Roth, T, Lubin, F, Sodhi, M, and JE, K. (2009). Epigenetic mechanisms in schizophrenia. Biochimica et Biophysica Acta , 869-877. Thompson, PM, Vidal, C, Giedd, JN, Gochman, P, Blumenthal, J, Nicolson, R, Toga, AW, and Rapoport, JL. (2001). Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. PNAS. 11650-11655. “The difference between genetics and epigenetics can probably be compared to the difference between writing and reading a book. Once a book is written, the text (the genes or DNA: stored information) will be the same in all the copies distributed to the interested audience. However, each individual reader of a given book may interpret the story slightly differently, with varying emotions and projections as they continue to unfold the chapters. In a very similar manner, epigenetics would allow different interpretations of a fixed template (the book or genetic code) and result in different read- outs, dependent upon the variable conditions under which this template is interrogated.” - Thomas Jenuwein (Vienna, Austria) (Thompson, et. al., 2001) (Narr, et al., 2000) Background image courtesy of The Royal Society of New Zealand (http://nihroadmap.nih.gov/EPIGENOMICS/images/epigeneticmechanisms) Conclusions Recent research provides evidence that although schizophrenia is affected by genetics, epigenetics play a major role in the development of the disorder, as well. Environmental conditions an individual encounters during his life both in his mother’s womb and after birth lead to methylation, acetylation, and phosphorylation of DNA and histone tails. These modifications, though normal, may lead to severe consequences if done in specific areas of the brain and within certain genes. Methylation of the promoters of certain genes, such as GAD67, are obvious causes of schizophrenia. Emerging neurobiological evidence indicates that many of the genes potentially involved in etiology of schizophrenia may also be involved in pathology of bipolar disorder and to a lesser degree in major depression and other neurodevelopmental disorders like autism (Fatemi, Stary, Earle, Araghi-Niknam, & Eagan, 2005). By studying the major epigenetic mechanisms implicated in schizophrenia and these other disorders, it seems we are paving a road toward treatment and prevention.